Biotechnology Equity
AXA Framlington Biotech
Last updated: 2026-03-13
The Verdict
AXA Framlington Biotech charges an expense ratio of 1.57%. On a $100,000 portfolio, that's $1,570 per year in fees. Supreme.PM's decoded model provides similar exposure at a fraction of the cost, potentially saving $1,320 per year.
Expense Ratio
1.57%
Star Rating
3/ 5
Market Beta
0.89
Supreme.PM Cost
0.25%
Annual platform fee
Fee Analysis
AXA Framlington Biotech charges 1.57% annually. Supreme.PM offers equivalent exposure for 0.25%, a savings of 1.32 percentage points.
Data sources: Refinitiv Lipper, SEC EDGAR Filings, Supreme.PM Analytics
Past performance does not guarantee future results. Model returns are backtested and may not reflect actual trading conditions.
Related
Biotechnology Equity Category
Browse all Biotechnology Equity funds
Biotechnology Equity Rankings
Top-rated Biotechnology Equity funds
Our Methodology
How we decode fund strategies
Candriam Equities Biotechnology
3-star rated
Pictet-Biotech
1-star rated
Polar Capital Biotechnology
5-star rated
International Biotechnology Trust
Candriam Equities Biotechnology
5-star rated
Frequently Asked Questions
What is the expense ratio of AXA Framlington Biotech?
AXA Framlington Biotech has an expense ratio of 1.57%. Supreme.PM's decoded model provides similar exposure at a significantly lower cost.
How does Supreme.PM replicate AXA Framlington Biotech?
Supreme.PM uses AI to analyze the fund's holdings and trading patterns, creating a decoded model that tracks the fund's performance.
What are the risks of fund replication?
While our models aim for high correlation, they may not perfectly match the fund's returns due to timing differences in rebalancing, transaction costs, and disclosure delays. Backtested results may not reflect future performance.
Get This Strategy
Start investing with Supreme.PM's decoded model and save on fees while capturing similar returns.